This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Mutation Analysis of TP53 in Colorectal Cancer, Peshawar, Khyber Pakhtunkhwa, Pakistan.
Mian Adnan Kakakhel
Lanzhou University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Declarations:
Declarations
- This study involved human subjects.
- The author confirmed that all appropriate ethical guidelines for the use of human subjects have been followed, any necessary IRB and/or ethics committee review has been obtained, and information about the IRB/ethics committee is included in the manuscript.
- The author has confirmed that all necessary patient/participant consent or assent has been obtained and the appropriate institutional forms have been archived. If the IRB/ethics committee waived the requirement for patient/participant consent or assent, an explanation for the waiver is included in the text.
- The author has confirmed that a statement listing potential conflicts of interest or lack thereof is included in the text.
Background Colorectal cancer is a kind of solid tumor and third most common of cancer which leads to death. It is a heterogeneous disease characterized by genetic and epigenetic aberrations. For this purpose, a total of 50 blood samples in EDTA tubes was collected from Peshawar with complete information of patients using questionnaire
Result The results of the present study indicate that the ratio of CRC in males is higher 62% than females (38%). Histopathological results indicate that moderately differentiated adenocarcinoma is 25 (50%) followed by poorly differentiated adenocarcinoma 15 (30%), Well-differentiated adenocarcinoma 8 (16%), and Metastatic adenocarcinoma 2 (4%) in 50 CRC patients. Grading distribution indicating 34% of patients were having a high grade of carcinoma while 66% had low-grade carcinoma. The nucleotide sequence of the human TP53 gene of CRC patients was aligned with the human wild-type TP53 database sequence with NC_191170 (NCBI) using CLUSTALW. After BLASTING, the mutation was found in exon 5 and exon 7 of TP53, while no mutation was found in exon 8 of TP53. That patient in which point mutation was found in exon 5 and 7 respectively showed less survival as compared to that of colorectal cancer patients having no point mutation in the TP53 gene.
Conclusion The present study concluded that point mutations were found in exons 5 & 7 of the TP53 gene and patients having TP53 gene mutations shown less survival rate compared to CRC patients having no mutations.
Keywords
Cancer, Mutation, TP53 Gene, PCR, Blasting
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 18 Dec, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
Learn more about our company.
This is a preprint. It has not completed peer review.
Research Article
Mutation Analysis of TP53 in Colorectal Cancer, Peshawar, Khyber Pakhtunkhwa, Pakistan.
Mian Adnan Kakakhel
Lanzhou University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 18 Dec, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Declarations:
Declarations
- This study involved human subjects.
- The author confirmed that all appropriate ethical guidelines for the use of human subjects have been followed, any necessary IRB and/or ethics committee review has been obtained, and information about the IRB/ethics committee is included in the manuscript.
- The author has confirmed that all necessary patient/participant consent or assent has been obtained and the appropriate institutional forms have been archived. If the IRB/ethics committee waived the requirement for patient/participant consent or assent, an explanation for the waiver is included in the text.
- The author has confirmed that a statement listing potential conflicts of interest or lack thereof is included in the text.
Background Colorectal cancer is a kind of solid tumor and third most common of cancer which leads to death. It is a heterogeneous disease characterized by genetic and epigenetic aberrations. For this purpose, a total of 50 blood samples in EDTA tubes was collected from Peshawar with complete information of patients using questionnaire
Result The results of the present study indicate that the ratio of CRC in males is higher 62% than females (38%). Histopathological results indicate that moderately differentiated adenocarcinoma is 25 (50%) followed by poorly differentiated adenocarcinoma 15 (30%), Well-differentiated adenocarcinoma 8 (16%), and Metastatic adenocarcinoma 2 (4%) in 50 CRC patients. Grading distribution indicating 34% of patients were having a high grade of carcinoma while 66% had low-grade carcinoma. The nucleotide sequence of the human TP53 gene of CRC patients was aligned with the human wild-type TP53 database sequence with NC_191170 (NCBI) using CLUSTALW. After BLASTING, the mutation was found in exon 5 and exon 7 of TP53, while no mutation was found in exon 8 of TP53. That patient in which point mutation was found in exon 5 and 7 respectively showed less survival as compared to that of colorectal cancer patients having no point mutation in the TP53 gene.
Conclusion The present study concluded that point mutations were found in exons 5 & 7 of the TP53 gene and patients having TP53 gene mutations shown less survival rate compared to CRC patients having no mutations.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8